These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 12490967

  • 21. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G, Bruckert E.
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [Abstract] [Full Text] [Related]

  • 22. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
    Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, Elisaf M, Mikhailidis DP.
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):127-34. PubMed ID: 12808486
    [Abstract] [Full Text] [Related]

  • 23. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
    Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J.
    J Biol Chem; 2004 Jul 02; 279(27):28662-9. PubMed ID: 15123680
    [Abstract] [Full Text] [Related]

  • 24. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB, Peters JR.
    Am J Med; 1987 Nov 27; 83(5B):44-9. PubMed ID: 3318453
    [Abstract] [Full Text] [Related]

  • 25. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG.
    Am J Cardiol; 1997 Sep 01; 80(5):608-13. PubMed ID: 9294990
    [Abstract] [Full Text] [Related]

  • 26. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M, Frohlich J.
    Vnitr Lek; 2000 Mar 01; 46(3):152-6. PubMed ID: 11048517
    [Abstract] [Full Text] [Related]

  • 27. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M, Fedelesova V, Mongiellova V, Cibulova L, Huttova D, Polak F, Krivosikova Z.
    Bratisl Lek Listy; 1999 Aug 01; 100(8):449-53. PubMed ID: 10645034
    [Abstract] [Full Text] [Related]

  • 28. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
    Nikkilä EA, Ylikahri R, Huttunen JK.
    Proc R Soc Med; 1976 Aug 01; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
    [Abstract] [Full Text] [Related]

  • 29. [Effectiveness of ciprofibrate. Open study in a Portuguese population].
    Silva JM, Branco MC, Pereira M, Figueiredo H, Jesus LC, de Moura JP, Ferreira MR, Serra e Silva P.
    Rev Port Cardiol; 1995 Apr 01; 14(4):313-22, 284. PubMed ID: 7612280
    [Abstract] [Full Text] [Related]

  • 30. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J, CAP Investigators.
    Clin Ther; 2008 Dec 01; 30(12):2298-313. PubMed ID: 19167589
    [Abstract] [Full Text] [Related]

  • 31. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
    Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP.
    Int J Cardiol; 1999 Jun 01; 69(3):237-44. PubMed ID: 10402106
    [Abstract] [Full Text] [Related]

  • 32. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.
    Ginsberg HN, Le NA, Gibson JC.
    J Clin Invest; 1985 Feb 01; 75(2):614-23. PubMed ID: 3973021
    [Abstract] [Full Text] [Related]

  • 33. Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension.
    Lepira FB, M'Buyamba-Kabangu JR, Kayembe KP, Nseka MN.
    Cardiovasc J S Afr; 2005 Feb 01; 16(5):249-55. PubMed ID: 16307156
    [Abstract] [Full Text] [Related]

  • 34. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M, Torbus-Lisiecka B, Pieczul-Mróz J, Chelstowski K, Kopciewicz J, Naruszewicz M.
    Int J Clin Pharmacol Res; 1999 Feb 01; 19(1):19-25. PubMed ID: 10450539
    [Abstract] [Full Text] [Related]

  • 35. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
    Nagyová A, Raslová K, Ginter E.
    Physiol Res; 1998 Feb 01; 47(3):185-90. PubMed ID: 9803483
    [Abstract] [Full Text] [Related]

  • 36. Comparative hypolipidaemic and peroxisomal effects of ciprofibrate, clofibric acid, and their respective difluorocyclopropyl and 4-fluoro-substituted analogues in rat.
    Graham MJ, Winham MA, Old SL, Gray TJ.
    Xenobiotica; 1996 Jul 01; 26(7):695-707. PubMed ID: 8819300
    [Abstract] [Full Text] [Related]

  • 37. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ, O'Bryan-Tear CG.
    Postgrad Med J; 1996 Dec 01; 72(854):739-43. PubMed ID: 9015467
    [Abstract] [Full Text] [Related]

  • 38. Ciprofibrate--racemate and enantiomers: effects of a four-week treatment on male inbred Fischer rats. A biochemical and morphological study.
    Klinger W, Lupp A, Karge E, Oelschläger H, Rothley D, Danz M, Linss W, Löbel S, Deufel T, Müller M, Klinger M, Kühnel W.
    Exp Toxicol Pathol; 1998 Sep 01; 50(4-6):301-14. PubMed ID: 9784002
    [Abstract] [Full Text] [Related]

  • 39. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI, Schreier L, Elbert A, Berg G, Beresan H, López G, Wikinski R.
    Metabolism; 2003 Jan 01; 52(1):116-21. PubMed ID: 12524671
    [Abstract] [Full Text] [Related]

  • 40. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
    de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C.
    Thromb Haemost; 1997 Jan 01; 77(1):75-9. PubMed ID: 9031453
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.